QUANTIFICATION OF CD1A+ LANGERHANS CELLS IN ORAL EPITHELIAL DYSPLASIA AND ORAL SQUAMOUS CELL CARCINOMA

Authors

  • Sardar Waleed Babar Department of Histopathology, Armed Forces Institute of Pathology / National University of Medical Sciences, Rawalpindi-Pakistan https://orcid.org/0009-0009-8239-6099
  • Muhammad Asif Department of Histopathology, Armed Forces Institute of Pathology / National University of Medical Sciences, Rawalpindi-Pakistan
  • Farwa Zaheer Department of General Pathology, Shifa College of Medicine/Shifa Tameer-e-Millat University, Islamabad-Pakistan
  • Amna Ameer Department of Histopathology, Armed Forces Institute of Pathology / National University of Medical Sciences, Rawalpindi-Pakistan
  • Azka Haroon Department of Histopathology, Armed Forces Institute of Pathology / National University of Medical Sciences, Rawalpindi-Pakistan https://orcid.org/0009-0004-4332-9014
  • Sadia Minhas Department of Oral Pathology, Akhtar Saeed Medical and Dental College, Lahore-Pakistan

DOI:

https://doi.org/10.55519/JAMC-01-12828

Keywords:

CD1a, Langerhans cell, oral epithelial dysplasia, oral squamous cell carcinoma, tumour progression, immune response

Abstract

Background: To quantify the immunohistochemical expression of CD1a positive Langerhans cell population and find their association with tumour progression in oral epithelial dysplasia and oral squamous cell carcinoma. Methods: A total of 119 biopsies were collected out of which 61 were oral epithelial dysplasia (20 mild, 20 moderate, 21 severe) and 58 were oral squamous cell carcinoma (well differentiated only). Fresh haematoxylin and eosin slides were prepared followed by application of CD1a immunohistochemical marker to quantify Langerhans cell in epithelium and connective tissue separately. To compare quantitative results One Way ANOVA and Independent Sample T test was used. ≤0.05 was considered a significant p-value. Results: A statistically significant association between CD1a+ Langerhans cell count and advancing degrees of dysplasia to well differentiated oral squamous cell carcinoma in both epithelium (<0.05) and connective tissue (<0.05) was seen. Significant difference was also seen when oral epithelial dysplasia was compared with well differentiated oral squamous cell carcinoma in epithelium (p<0.05) but, no significant difference (p>0.05) was seen in case of connective tissue. Conclusion: The mean CD1a+ Langerhans cell count decreased with increase in degree of dysplasia and an increase in well differentiated oral squamous cell carcinoma was seen which needs further studies. Mean CD1a+ LC count can be used as a tool for highlighting disease progression for epithelial dysplasia and increase in mean CD1a+ Langerhans cell in oral squamous cell carcinoma can be argued with its better prognosis among other histological grades of this carcinoma.

Author Biography

Sardar Waleed Babar, Department of Histopathology, Armed Forces Institute of Pathology / National University of Medical Sciences, Rawalpindi-Pakistan

Correspondence:

Department of Histopathology, Armed Forces Institute of Pathology / National University of Medical Sciences, Rawalpindi-Pakistan

Cell: +92 331 566 8965

Email: sardarwaleedbabar@gmail.com

References

1. Al-Jamaei A, van Dijk B, Helder M, Forouzanfar T, Leemans C, de Visscher J. A population-based study of the epidemiology of oral squamous cell carcinoma in the Netherlands 1989–2018, with emphasis on young adults. Int J Oral Maxillofac Surg 2022;51(1):18–26.

2. Singh S, Singh J, Chandra S, Samadi FM. Prevalence of oral cancer and oral epithelial dysplasia among North Indian population: A retrospective institutional study. J Oral Maxillofac Pathol 2020;24(1):87–92.

3. Patil S, Rao R, Amrutha N, Sanketh D. Analysis of human papilloma virus in oral squamous cell carcinoma using p16: An immunohistochemical study. J Int Soc Prev Community Dent 2014;4(1):61–6.

4. Capote-Moreno A, Brabyn P, Muñoz-Guerra M, Sastre-Pérez J, Escorial-Hernandez V, Rodríguez-Campo F, et al. Oral squamous cell carcinoma: epidemiological study and risk factor assessment based on a 39-year series. Int J Oral Maxillofac Surg 2020;49(12):1525–34.

5. Da Silva LC, Fonseca FP, de Almeida OP, de Almeida Mariz BAL, Lopes MA, Radhakrishnan R, et al. CD1a+ and CD207+ cells are reduced in oral submucous fibrosis and oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2020;25(1):e49–55.

6. Ni YH, Zhang XX, Lu ZY, Huang XF, Wang ZY, Yang Y, et al. Tumor-infiltrating CD1a+ DCs and CD8+/FoxP3+ ratios served as predictors for clinical outcomes in tongue squamous cell carcinoma patients. Pathol Oncol Res 2020;26(3):1687–95.

7. Lasisi TJ, Oluwasola AO, Lasisi OA, Akang EE. Association between langerhans cells population and histological grade of oral squamous cell carcinoma. J Oral Maxillofac Pathol 2013;17(3):329–33.

8. Gooty JR, Kannam D, Guntakala VR, Palaparthi R. Distribution of dendritic cells and langerhans cells in peri-implant mucosa. Contemp Clin Dent 2018;9(4):548–53.

9. Gomes JO, de Vasconcelos Carvalho M, Fonseca FP, Gondak RO, Lopes MA, Vargas PA. CD 1a+ and CD 83+ Langerhans cells are reduced in lower lip squamous cell carcinoma. J Oral Pathol Med 2016;45(6):433–9.

10. Pellicioli ACA, Bingle L, Farthing P, Lopes MA, Martins MD, Vargas PA. Immunosurveillance profile of oral squamous cell carcinoma and oral epithelial dysplasia through dendritic and T‐cell analysis. J Oral Pathol Med 2017;46(10):928–33.

11. Wang YP, Chen IC, Wu YH, Wu YC, Chen HM, Chang JYF. Langerhans cell counts in oral epithelial dysplasia and their correlation to clinicopathological parameters. J Formos Med Assoc 2017;116(6):457–63.

12. WHO. 90% of smokeless tobacco users live in South-East Asia. [Internet]. World Health Organization 2013, September 11 [cited 2024 Jan]. Available from: https://www.who.int/southeastasia/news/detail/11-09-2013-90-of-smokeless-tobacco-users-live-in-south-east-asia

13. Öhman J, Magnusson B, Telemo E, Jontell M, Hasséus B. Langerhans cells and T cells sense cell dysplasia in oral leukoplakias and oral squamous cell carcinomas–evidence for immunosurveillance. Scand J Immunol 2012;76(1):39–48.

14. Nikfarjam S, Rezaie J, Kashanchi F, Jafari R. Dexosomes as a cell-free vaccine for cancer immunotherapy. J Exp Clin Cancer Res 2020;39(1):258.

15. Narayanan B, Narasimhan M. Langerhans cell expression in oral submucous fibrosis: an immunohistochemical analysis. J Clin Diagn Res 2015;9(7):ZC39–41.

16. Jaitley S, Saraswathi T. Pathophysiology of Langerhans cells. J Oral Maxillofac Pathol 2012;16(2):239–44.

17. Hunger RE, Sieling PA, Ochoa MT, Sugaya M, Burdick AE, Rea TH, et al. Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. J Clin Invest 2004;113(5):701–8.

18. Jardim JF, Gondak R, Galvis MM, Pinto CA, Kowalski LP. A decreased peritumoral CD 1a+ cell number predicts a worse prognosis in oral squamous cell carcinoma. Histopathology 2018;72(6):905–13.

19. Abidi F, Hosein M, Butt SA, Baig F, Ahmed R, Zaidi AB. Immunohistochemical Expression of Nibrin in Epithelial Dysplasia and OSCC: A Cross-Sectional Study. J Adv Med Med Res 2021;33(6):42–8.

20. Kiani MN, Asif M, Ansari FM, Ara N, Ishaque M, Khan AR. Diagnostic utility of Cytokeratin 13 and Cytokeratin 17 in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma. Asian Pac J Cancer Biol 2020;5(4):153–8.

21. Akram S, Mirza T, Mirza MA, Qureshi M. Emerging patterns in clinico-pathological spectrum of oral cancers. Pak J Med Sci 2013;29(3):783–7.

22. Swetha D. Quantitative Estimation of Langerhans Cells in Normal Oral Mucosa, Inflammatory Mucositis, Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma using Cd1a Antibody: An Immunohistochemical study: Sree Mookambika Institute of Dental Sciences, Kulasekharam; 2019.

23. Morse DE, Psoter WJ, Cleveland D, Cohen D, Mohit-Tabatabai M, Kosis DL, et al. Smoking and drinking in relation to oral cancer and oral epithelial dysplasia. Cancer Causes Control 2007;18(9):919–29.

24. Upadhyay J, Rao NN, Upadhyay RB. A comparative analysis of langerhans cell in oral epithelial dysplasia and oral squamous cell carcinoma using antibody CD-1a. J Cancer Res Ther 2012;8(4):591–7.

25. Girod S, Kühnast T, Ulrich S, Krueger G. Langerhans cells in epithelial tumors and benign lesions of the oropharynx. In Vivo 1994;8(4):543–7.

26. Bondad-Palmario GG. Histological and immunochemical studies of oral leukoplakia: Phenotype and distribution of immunocompetent cells. J Philipp Dent Assoc 1994;36(2):87–100.

27. Coventry B, Heinzel S. CD1a in human cancers: a new role for an old molecule. Trends Immunol 2004;25(5):242–8.

28. Kindt N, Descamps G, Seminerio I, Bellier J, Lechien JR, Pottier C, et al. Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas. Oral Oncol 2016;62:1–10.

29. Araújo CP, Gurgel CAS, Ramos EAG, Freitas VS, Júnior AdAB, Ramalho LMP, et al. Accumulation of CD1a-positive Langerhans cells and mast cells in actinic cheilitis. J Mol Histol 2010;41(6):357–65.

30. Vargas PA, Pellicioli ACA, Martins MD, Farthing P, Speight P, Lopes MA, et al. Expression of dendritic, langerhans and t cells in potentially malignant lesions and oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2017;124(2):e138–9.

31. Rani SV, Aravindha B, Leena S, Balachander N, Malathi LK, Masthan MK. Role of abnormal Langerhans cells in oral epithelial dysplasia and oral squamous cell carcinoma: A pilot study. J Nat Sci Biol Med 2015;6(Suppl 1):S128.

Published

2025-04-15

How to Cite

1.
Babar SW, Asif M, Zaheer F, Ameer A, Haroon A, Minhas S. QUANTIFICATION OF CD1A+ LANGERHANS CELLS IN ORAL EPITHELIAL DYSPLASIA AND ORAL SQUAMOUS CELL CARCINOMA. J Ayub Med Coll Abbottabad [Internet]. 2025 Apr. 15 [cited 2025 Jul. 19];37(1). Available from: https://www.jamc.ayubmed.edu.pk/index.php/jamc/article/view/12828

Issue

Vol. 37 No. 1 (2025): JOURNAL OF AYUB MEDICAL COLLEGE ABBOTTABAD

Section

ORIGINAL ARTICLE

License

Copyright (c) 2025 Sardar Waleed Babar, Muhammad Asif, Farwa Zaheer, Amna Ameer, Azka Haroon, Sadia Minhas

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License  CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.

USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.